Hone Health, an online clinic that began by treating men with low testosterone, announced Wednesday it has secured $228 million in new financing, including a $28 million equity round led by MarcyPen Capital Partners, the investment firm co-founded by Shawn "Jay-Z" Carter, and backing from Gwyneth Paltrow's firm.
The equity round was led by MarcyPen Capital Partners, which also led Hone's Series A, a role the company had not previously made public. Hone said in a statement that MarcyPen "has historically maintained a low public profile, allowing their portfolio companies to remain at the center of their own stories."
Other backers in the equity round include Kinship Ventures, the firm Gwyneth Paltrow co-founded with Moj Mahdara, along with Pentland Ventures, Hanwha, Gannet Capital, and Humbition. Individual investors include the Jonas Brothers, singer Kelly Rowland, actor Marcello Hernández, and hospitality entrepreneurs David Grutman, Jason Strauss and Noah Tepperberg.
Paltrow said she is also a patient. "I did all my labs and blood work and everything. I started a protocol that was incredibly helpful," she said. "We found gut bacteria; my hormones were unbalanced. It’s amazing how everything turned right side up."
Hone was co-founded in 2020 by Saad Alam, who told Fortune that after months of visits to specialists, a group of doctors told him he had low testosterone. The clinic started by treating men with low testosterone.
Of the $228 million, $200 million comes from General Catalyst's Customer Value Fund, which pays for a large share of a company's sales and marketing and is repaid from the revenue the new customers bring in. Alam said he can call General Catalyst each month and ask for $10 million, spend it acquiring patients, then pay back a portion of the profit from those patients plus interest. Unlike a bank loan, he said, the deal has no recourse and no covenants restricting Hone from raising other money.
Hone broke through $100 million in recurring revenue last year, according to Alam, and has treated about 200,000 patients since it launched. The new round brings Hone's total equity funding to $65 million. Alam said most of the $28 million will go to AI that lets one physician handle problems that would normally send a patient to several specialists.
Hone is also launching Hone Black, a concierge membership that has run in stealth for a small group of high-profile patients. It pairs testing of more than 1,600 health markers with a dedicated team of physicians. Alam calls it a test bed for treatments that may later reach Hone's main product.
Alam said Hone is the first business under a parent company, Time Therapeutics. His plan has three stages: build a large online clinic, use its patient base to run clinical trials remotely, then partner with drugmakers and research centers to bring drugs to market faster in exchange for equity.
Analysis
Why This Matters
- The infusion of celebrity capital signals growing mainstream interest in longevity and personalised health management
- Hone's hybrid model of equity and a revenue-based financing deal from General Catalyst may become a template for other health startups scaling marketing spend
- The launch of Hone Black, a concierge tier for high-profile patients, could accelerate the adoption of advanced diagnostics and therapies
Background
Hone Health is an online clinic founded in 2020 that initially focused on treating men with low testosterone. It has since expanded to offer broader hormone and metabolic testing. The company treats patients remotely, using lab results to create personalised protocols. Its parent company, Time Therapeutics, plans to eventually use its patient base to run remote clinical trials and partner with drugmakers.
Key Perspectives
Saad Alam (Hone Health cofounder): said the doctor who diagnosed him dismissed his symptoms, leading him to start the company. Of MarcyPen, he said "Here's the capital. You guys let the company do all the work, and we want the company to shine—not necessarily everyone that's surrounding it."
Jay Brown (MarcyPen Capital Partners): said "Saad and the team at Hone are proven business builders dedicated to making it easier for people to live better, healthier lives."
Gwyneth Paltrow (investor and patient): said after doing her labs and blood work she "started a protocol that was incredibly helpful" and that "it’s amazing how everything turned right side up."
Kelly Rowland (investor): said she wants more people, "especially women," to take control of their health. "I want to be stronger in my 50s than I was in my 30s."
Noah Tepperberg (investor): said he has started referring family and friends and when asked if he sees himself as an investor or promoter, said "all of the above."
Jason Strauss (investor): said he has been into longevity medicine "for decades." "I live a very demanding lifestyle and I want to not only feel my best today, but live as many years as possible in good health."
Omar Hatteea (Pentland Ventures): said "People have never had more data about their own bodies and never less guidance on what to do with it."
Charlie Hanna (MarcyPen managing director): said the firm has "been incredibly impressed by their ambition and execution."
What to Watch
- Whether Hone can sustain its revenue growth and patient retention to keep the General Catalyst deal favourable
- How the Hone Black concierge program's experimental treatments are received and whether they translate into mainstream offerings
- The progress of Time Therapeutics' three-stage plan and any partnerships with drugmakers or research centres